Teriparatide biosimilar (Rhein Minapharm Biogenetics)

特立帕肽生物类似药 (Rhein Minapharm Biogenetics)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTeriparatide biosimilar (Rhein Minapharm Biogenetics)
Drug Alias NameModified PTH特立帕肽生物仿制药 (Rhein Minapharm Biogenetics)
ClassificationBiologics > Protein drugs > Recombinant polypeptideBiologics > Biosimilar
Mechanisms of ActionParathyroid hormone replacements
TargetsParathyroid hormone receptor
Therapy Area/IndicationsOsteoporosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Clinical)
Highest Status in ChinaN/A
Originator CompaniesRhein Minapharm Biogenetics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRhein Minapharm Biogenetics
Active IndicationsN/A
Inactive IndicationsOsteoporosis

Other Information

ATC CodeH05AA02
Related LinksN/A